

SEQUENCE LISTING



<110> Celmed Oncology (USA), Inc.  
Shepard, Michael H.

<120> Methods for treating therapy-resistant tumors

<130> 060925-0601

<140> US 10/048,033  
<141> 2002-11-27

<150> PCT/US00/20007  
<151> 2000-07-21

<150> US 60/145,364  
<151> 1999-07-22

<150> US 60/153,855  
<151> 1999-09-14

<160> 6

<170> PatentIn version 3.3

<210> 1  
<211> 19  
<212> DNA  
<213> Artificial

<220>  
<223> Corresponding to bases 208-226 of thymidylate synthase cDNA sequence

<400> 1  
gggcagatcc aacacatcc 19

<210> 2  
<211> 20  
<212> DNA  
<213> Artificial

<220>  
<223> antisense primer corresponding to bases 564-583

<400> 2  
ggtcaactcc ctgtcctgaa 20

<210> 3  
<211> 19  
<212> DNA  
<213> Artificial

<220>  
<223> corresponding to bases 2643-2661 of b-actin gene sequence

<400> 3  
gccaacacag tgctgtctg 19

<210> 4  
<211> 19  
<212> DNA

<213> Artificial

<220>

<223> antisense primer corresponding to bases 2937-2955

<400> 4

ctcctgcttg ctgatccac

19

<210> 5

<211> 26

<212> DNA

<213> Artificial

<220>

<223> sense primer used for PCR amplification

<400> 5

cggaagcttg agccgcgtcc gccgca

26

<210> 6

<211> 26

<212> DNA

<213> Artificial

<220>

<223> antisense primer used for PCR amplification

<400> 6

gaaggtagcc taaacagcca tttcca

26